|Day Low/High||179.16 / 180.55|
|52 Wk Low/High||133.64 / 184.21|
Aimovig is an Investigative Migraine-Specific Preventive Therapy Designed for Patients With High Unmet Need
Array to Advance Preclinical Program for Autoimmune Disorders
Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent and Increased Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
First Amgen and Allergan Oncology Biosimilar Candidate to be Reviewed by U.S. FDA Advisory Committee
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone
BLINCYTO is the First-and-Only Bispecific T Cell Engager (BiTE®) Immunotherapy to Demonstrate Superior Overall Survival Versus Standard of Care Chemotherapy
Two Diagnostic Companies Will Receive Lab Space and Other Benefits at San Francisco Life Sciences Incubator
Sarah Hassan, daughter of pharmaceutical executive Fred Hassan, was ignored by Shkreli for nearly a year before she received returns on her original investment.
A tech selloff yields big Wall Street losses.
Vectibix Demonstrated an Improvement in Overall Survival in Patients With Wild-Type RAS Metastatic Colorectal Cancer
Tech, healthcare slide weighs on rest of markets.
Healthcare's slide weighs on rest of markets.
The iShares NASDAQ Biotechnology Index ended the five days ended Friday, June 23 up 26% to close at $370.74.
The main headwind for Regeneron is that Swiss pharma giant Novartis could soon be a rival to the eye drug that drives most of Regeneron's revenue.
The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.
Slowing sales and safety concerns have some investors less than enthused, but Amgen says it's drugs in development could deliver.
Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma
FDA Sets PDUFA Target Action Date of Feb. 3, 2018
Newly released neurotransmitter research could open up a $8 - $10 billion market as early as next year.
Data From Broad Clinical Program Show Investigational Erenumab is Effective at Preventing Migraine in Patients Experiencing Four or More Migraine Days a Month